Please note: The license is valid for 12 months from the date the report is sent.
Vaccines and their technology – your guide to developments, opportunities and revenues
See what the future holds for vaccines. Visiongain’s updated report lets you assess forecasted sales at overall world market, submarket, product and national level to 2025.
Make sure you understand trends, R&D, opportunities and prospects there, in human medicine. That way you can help your research, analysis and decisions. For those technologies, discover in our study what’s likely to happen. And find what gains are possible.
Vaccines still hold great technological, medical and commercial potential. See why. So please read on to explore that industry and hear what its future market could be worth.Forecasts from 2015 to 2025 and other analyses showing you commercial prospects
Besides revenue forecasting to 2025, our new work gives you historical data, recent results, growth rates and market shares. There you find business outlooks and developments (R&D).
You also get 50 tables, 49 charts and two interviews, with other opinion. That study includes our discussions with GSK and BiondVax Pharmaceuticals.Gains through understanding the vaccines sector – find advantages for your work
Leaders hold knowledge. So hear what’s happening for development, production and sales of those preventative medicines. There, from 2015, you see where needs and money exist.
And avoid struggles to gain business information. Instead use our predictions for vaccination to expand your business and help your influence. That way, benefit your authority and stay ahead.
Discover how you and your organisation can gain. The following sections reveal what you get in that new investigation.Revenues for the world vaccines market and submarkets
What’s that industry's potential? What’re the secrets of its progress? Discover in our report overall world revenue to 2025. Also find individual forecasts for main submarkets at world level:
- Paediatric vaccines
- Adult vaccines.
How will sales rise? See, then, which product classes can generate most revenue. There you assess prospects for commercial expansion. Discover now the money-earning potential.
Explore the market for vaccinations by brand too.Forecasts and discussions for leading marketed products
How will leading brands perform to 2025 at world level? Our work shows you 10 individual revenue forecasts to 2025 for top products:
- Prevnar group
- Varivax/M-M-R II/ProQuad.And also for these agents:
- Hepatitis group, GSK
There you assess potentials, seeing activities, results and outlooks. You discover what’s happening, understanding trends, competition and sales prospects. Assess the future, then, including prospects for newer agents.Newer vaccines and products in development – how will leading candidates perform?
Also see how newer agents, especially those in development and awaiting launch, can perform. For these 11 medicines, see revenues to 2025:
- Zoster and Malaria vaccines (GSK)
- 9-valent HPV agents (Merck)
- Hexavalent paediatric vaccines (Sanofi)
- Dengue fever products (Sanofi)
- Trumenba vaccines (Pfizer).And get forecasts for these treatments:
- C. difficile and S. aureus vaccines (Pfizer)
- Ebola vaccines (Johnson & Johnson)
- Dengue fever vaccines (Takeda)
- Universal influenza vaccines (BiondVax).
There you assess the future of that industry’s developments, finding sales gains possible.
Our study also divides its overarching world forecast into geographical regions.Healthcare in national markets – what outlooks for sales of those medicines?
Progress worldwide in vaccines and healthcare will expand vaccination.
Get Industry Insights. Simply.
- Latest reports & slideshows with insights from top research analysts
- 60 Million searchable statistics with tables, figures & datasets
- More than 25,000 trusted sources